跳至主要内容
临床试验/NL-OMON21784
NL-OMON21784已完成不适用

Atomoxetine for Attention-Deficit Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: a Pilot Study.

Accare, division University Center for Child and Adolescent Psychiatry, PO Box 660, 9700 AR Groningen, The Netherlands0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12

研究概览

简要总结

Pieter W. Troost, M.D., Mark-Peter Steenhuis, M.S., Hanneke G. Tuynman-Qua, M.D., Luuk Kalverdijk, M.D., Lawrence Scahill, M.S.N., Ph.D., Jan K. Buitelaar, M.D., Ph.D., Ruud B. Minderaa, M.D. Ph. D., Pieter J. Hoekstra, M.D., Ph. D. Atomoxetine for Attention-Deficit Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: a Pilot Study. Submitted.

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Males and females between the ages of at least 6 years of age and not more than 17 years of age at visit 1;
  • 2. ASD (DSM-IV TR diagnosis of autistic disorder or Asperger’s disorder or PDD not otherwise specified, established by clinical assessment and corroborated by Autism Diagnostic Interview scores;

排除标准

  • 1. Patients who weigh less than 20 kg at study entry;
  • 2. Females with a positive Beta HCG pregnancy test;

研究者

发起方
Accare, division University Center for Child and Adolescent Psychiatry, PO Box 660, 9700 AR Groningen, The Netherlands

相似试验